---
title: "Xarelto (rivaroxaban) in nonvalvular atrial fibrillation: Specific populations questions"
description: "Specific populations questions on Xarelto (rivaroxaban) in nonvalvular atrial fibrillation, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: How is Xarelto dosed for atrial fibrillation with kidney impairment or dialysis? 1 question quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/xarelto--nonvalvular-atrial-fibrillation/specific-populations"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Xarelto (rivaroxaban) in nonvalvular atrial fibrillation: Specific populations questions

Manufacturer: Janssen Pharmaceuticals, Inc.  
Prescribing information: [Xarelto](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf)

Specific populations questions that apply to every indication of Xarelto are on [Xarelto (rivaroxaban), all indications: Specific populations](https://www.evicenter.com/medical-information/xarelto/specific-populations).

## Specific populations

<a id="xarelto-kidney-dosing"></a>

### How is Xarelto dosed for atrial fibrillation with kidney impairment or dialysis?

> “In the ROCKET AF trial, patients with CrCl 30 to 50 mL/min were administered 
> XARELTO 15 mg once daily resulting in serum concentrations of rivaroxaban and 
> clinical outcomes similar to those in patients with better renal function 
> administered XARELTO 20 mg once daily. Patients with CrCl <30 mL/min were not 
> studied, but administration of XARELTO 15 mg once daily is expected to result in 
> serum concentrations of rivaroxaban similar to those in patients with moderate 
> renal impairment [see Clinical Pharmacology (12.3)].”

Source: [XARELTO: Prescribing information, page 11, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=11)

> “Clinical efficacy and safety studies with XARELTO did not enroll patients with 
> end-stage renal disease (ESRD) on dialysis. In patients with ESRD maintained on 
> intermittent hemodialysis, administration of XARELTO 15 mg once daily will result 
> in concentrations of rivaroxaban and pharmacodynamic activity similar to those 
> observed in the ROCKET AF study [see Clinical Pharmacology (12.2, 12.3)]. It is 
> not known whether these concentrations will lead to similar stroke reduction and 
> bleeding risk in patients with ESRD on dialysis as was seen in ROCKET AF.”

Source: [XARELTO: Prescribing information, page 11, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=11)

> “Periodically assess renal function as clinically indicated (i.e., more frequently in 
> situations in which renal function may decline) and adjust therapy accordingly [see 
> Dosage and Administration (2.1)]. Consider dose adjustment or discontinuation of 
> XARELTO in patients who develop acute renal failure while on XARELTO [see Use 
> in Specific Populations (8.6)].”

Source: [XARELTO: Prescribing information, page 6, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=6)

## Related pages
- [Medical information: Xarelto (rivaroxaban): Nonvalvular atrial fibrillation](https://www.evicenter.com/medical-information/xarelto--nonvalvular-atrial-fibrillation)
- [Indication](https://www.evicenter.com/medical-information/xarelto--nonvalvular-atrial-fibrillation/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/xarelto--nonvalvular-atrial-fibrillation/clinical-trials)
- [Real-world evidence](https://www.evicenter.com/medical-information/xarelto--nonvalvular-atrial-fibrillation/real-world-evidence)
- [Safety](https://www.evicenter.com/medical-information/xarelto--nonvalvular-atrial-fibrillation/safety)
- [Dosing and administration](https://www.evicenter.com/medical-information/xarelto--nonvalvular-atrial-fibrillation/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/xarelto--nonvalvular-atrial-fibrillation/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/xarelto--nonvalvular-atrial-fibrillation/guidelines)
